Febuxostat Tablets and Kaletra Oral Solution

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Potent inducers of UGT enzymes (e.g., rifampin, carbamazepine, phenobarbital, phenytoin, ritonavir) may increase the metabolism of febuxostat and decrease its therapeutic efficacy. Febuxostat undergoes extensive metabolism by both conjugation via UGT enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7, and oxidation via cytochrome P450 enzymes. The relative contribution of each isoenzyme and the clinical significance is unknown. Conversely, increased plasma levels of febuxostat may occur after a potent UGT inducer is discontinued.

Febuxostat Tablets

Generic Name: febuxostat

Brand name: Uloric

Synonyms: Febuxostat

What is Febuxostat Tablets?

Kaletra Oral Solution

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: Kaletra

What is Kaletra Oral Solution?